Lysyl oxidase isoforms in gastric cancer

Biomark Med. 2016 Sep;10(9):987-98. doi: 10.2217/bmm-2016-0075. Epub 2016 Aug 26.

Abstract

Gastric cancer (GC) is the fifth most frequent cancer in the world and shows the highest incidence in Latin America and Asia. An increasing amount of evidence demonstrates that lysyl oxidase isoforms, a group of extracellular matrix crosslinking enzymes, should be considered as potential biomarkers and therapeutic targets in GC. In this review, we focus on the expression levels of lysyl oxidase isoforms, its functions and the clinical implications in GC. Finding novel proteins related to the processing of these extracellular matrix enzymes might be helpful in the design of new therapies, which, in combination with classic pharmacology, could be used to delay the progress of this aggressive cancer and offer a wider temporal window for clinical intervention.

Keywords: Helicobacter pylori; basement membrane; collagen; copper depletion; extracellular matrix; fibrosis; gastric cancer; lysyl oxidase isoforms; tumor promoter; tumor suppressor.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Chelating Agents / therapeutic use
  • Collagen / metabolism
  • Elastin / metabolism
  • Fibrosis
  • Humans
  • Neoplasm Metastasis
  • Protein Isoforms / metabolism
  • Protein-Lysine 6-Oxidase / metabolism*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • Chelating Agents
  • Protein Isoforms
  • Collagen
  • Elastin
  • Protein-Lysine 6-Oxidase